New drug combo may stop hepatitis c spread in organ transplants
NCT ID NCT04508907
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a short course of two drugs (glecaprevir/pibrentasvir and ezetimibe) can prevent hepatitis C infection in people who receive a kidney, heart, lung, or pancreas from a donor with hepatitis C. About 200 participants who are hepatitis C-negative will take the drugs soon after transplant. The goal is to see if this approach stops the virus from taking hold and improves survival of both the patient and the transplanted organ.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Arizona
Phoenix, Arizona, 85054, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a thyroid hormone boost heart transplant success?
- Can a vaccine shield transplant patients from shingles?
- A Finger-Prick could change the fight against hepatitis c
- A simple finger prick could transform hepatitis c care
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can a single drug dose forecast transplant kidney health?